OCUL compared with MLTX: revenue, margins and what each company keeps, and the suppliers and customers both name

OCULOcular Therapeutix, Inc

Mkt capRevenueRevenue

MLTXMoonLake Immunotherapeutics

Mkt capRevenueRevenue

Compare

OCULOcular Therapeutix, Inc

MLTXMoonLake Immunotherapeutics

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

OCUL

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.6%▲+2.82%×0.21

Q1 FY26±8.0%▼−0.61%×0.07

Feb 5 '26±50.7%▲+4.21%×0.08

Nov 4 '25±10.3%▼−4.47%×0.44

MLTX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±23.0%▼−5.09%×0.22

= impliedOCUL realized, solidMLTX realized, hatchedOne scale, both sides: full bar = 51%× = |realized| ÷ impliedSource: market data

OCULOcular Therapeutix, Inc

6.73▼−3.52%· post 6.73· delayed

Mkt cap$1.5BRevenue$13MQ2 FY26Revenue$52MFY25

MLTXMoonLake Immunotherapeutics

11.47▼−2.64%· post 11.51· delayed

After hoursNov 2 '26delayed

Mkt cap$1.0BRevenue—Revenue—

Compare

After hoursNov 2 '26delayed

OCULOcular Therapeutix, Inc

MLTXMoonLake Immunotherapeutics

6.73▼−3.52%post 6.73delayed

Price

11.47▼−2.64%post 11.51delayed

$1.5B

Mkt cap

$1.0B

Q2 FY26$13M

Revenue

—

FY25$52M

Revenue

—

OCUL6.73▼−3.52%vsMLTX11.47▼−2.64%After hoursNov 2 '26delayed